- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr. Welsh on New Understanding of Regulating PD-L1 Expression
April 21st 2015, 7:32am
James Welsh, MD, associate professor of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses a study that examined the regulation of PD-L1 and how it may open up more treatment options for patients with non-small cell lung cancer.
HPV Vaccine May Benefit Women Previously Exposed to the Virus
April 21st 2015, 6:11am
HPV vaccination may offer protection against HPV-related cancers across multiple tumor sites in women aged 18-25 who had been previously exposed to HPV.
Adding Nivolumab to Frontline Ipilimumab Improves PFS by 60% in Melanoma
April 20th 2015, 12:39pm
Frontline immunotherapy with nivolumab plus ipilimumab delayed disease progression by 60% compared with ipilimumab alone in patients with advanced melanoma.
Dr. Hodi on Nivolumab in Combination With Ipilimumab for Advanced Melanoma
April 20th 2015, 10:19am
F. Stephen Hodi, MD, discusses the results of a trial presented at the 2015 AACR Annual Meeting.
Anti-PD-L1 Agent MPDL3280A Shows Durable Responses in TNBC
April 20th 2015, 8:56am
The PD-L1 inhibitor MPDL3280A demonstrated a 19% objective response rate (ORR) with 75% of responses ongoing in pretreated patients with metastatic triple-negative breast cancer.
Long-term Aspirin Use Decreases Risk of GI Cancers, Especially Colorectal
April 20th 2015, 7:32am
A recent study joins a body of evidence suggesting that long-term, regular aspirin use is associated with a reduced risk for cancer, with the most dramatic reduction being seen in colorectal cancer incidence.
Dr. Evan Alley on KEYNOTE-028 Trial Results in Mesothelioma
April 20th 2015, 7:25am
Evan W. Alley, MD, PhD, discusses the results from the phase Ib KEYNOTE-028 trial on a cohort of patients with malignant pleural mesothelioma.
MM-302 Shows Clinical Activity, Tolerability in Heavily-Pretreated HER2+ Breast Cancer
April 20th 2015, 6:23am
MM-302, a novel antibody-drug conjugate that specifically targets cancer cells overexpressing the HER2 receptor, showed signs of clinical activity in heavily pretreated patients with metastatic, HER2-positive breast cancer.
Pembrolizumab Nears 50% Response in High PD-L1-Expressing NSCLC
April 19th 2015, 4:40pm
Pembrolizumab had an overall response rate (ORR) of 45.2% among a cohort of patients with PD-L1-positive non–small cell lung cancer (NSCLC) and an ORR of nearly 20% in the full population in the phase I KEYNOTE-001 trial.
Breakthrough T-Cell Therapy Halts EBV-Associated Lymphoproliferative Disorders
April 19th 2015, 4:35pm
Infusions of Epstein-Barr virus (EBV)–specific cytotoxic T lymphocytes from healthy donors led to high response rates and significant extensions in overall survival for patients with rituximab-refractory EBV–associated lymphoproliferative disorders.
Frontline Pembrolizumab Trumps Ipilimumab in Head-to-Head Melanoma Trial
April 19th 2015, 4:30pm
Pembrolizumab elicited significantly better outcomes compared with ipilimumab in a randomized phase III trial of patients with advanced melanoma.
Dr. Heymach on New KRAS Subsets in Lung Cancer
April 19th 2015, 11:57am
John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology, MD Anderson Cancer Center, discusses a study on KRAS mutations in lung cancer, which led to the identification of three more KRAS subsets.
Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma
April 19th 2015, 8:45am
IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.
Fosbretabulin/Bevacizumab Combo Delays Progression, But Doubles Hypertension in Ovarian Cancer
March 31st 2015, 10:12am
Fosbretabulin plus bevacizumab lowered the risk of progression by 31.5% but doubled the rate of hypertension compared with bevacizumab alone in patients with recurrent ovarian cancer.
Bevacizumab Regimen Shows Survival Trend in Phase III Ovarian Cancer Trial
March 30th 2015, 4:15pm
Treatment with bevacizumab plus a chemotherapy doublet extended overall survival by nearly 5 months compared with chemotherapy alone for women with platinum-sensitive recurrent ovarian cancer.
Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer
March 30th 2015, 4:09pm
Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.
Studies Illuminate Olaparib's Continued Role in Ovarian Cancer
March 30th 2015, 6:00am
Analyses of clinical trials continue to illuminate the role of the PARP inhibitor olaparib in the treatment of women with ovarian cancer, according to Ursula A. Matulonis, MD.
Studies of Second-Line Immunotherapies in Bladder Cancer Hold Promise
March 16th 2015, 1:28pm
Interdisciplinary Prostate Cancer Congress
With no major advances in survival in bladder cancer in more than 30 years, interest is high in the potential to deploy immunotherapeutic approaches in this setting.
Gomella Discusses Optimizing Sipuleucel-T in mCRPC
March 16th 2015, 1:07pm
Interdisciplinary Prostate Cancer Congress
In an interview with OncLive, Leonard G. Gomella discusses the benefits, limitations, and considerations of sipuleucel-T for patients with prostate cancer.
Dr. Benson on Challenges of Active Surveillance for Prostate Cancer
March 16th 2015, 12:45pm
Interdisciplinary Prostate Cancer Congress
Mitchell Benson, MD, the Herbert and Florence Irving Professor at Columbia University Medical Center, New York-Presbyterian Hospital, discusses potential issues with active surveillance for patients with intermediate-risk prostate cancer.